Ellen K. Ritchie
About
Ellen K. Ritchie is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Ellen K. Ritchie has authored 172 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Hematology, 81 papers in Genetics and 48 papers in Molecular Biology. Recurrent topics in Ellen K. Ritchie's work include Acute Myeloid Leukemia Research (95 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (61 papers) and Chronic Myeloid Leukemia Treatments (57 papers). Ellen K. Ritchie is often cited by papers focused on Acute Myeloid Leukemia Research (95 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (61 papers) and Chronic Myeloid Leukemia Treatments (57 papers). Ellen K. Ritchie collaborates with scholars based in United States, Italy and France. Ellen K. Ritchie's co-authors include Gail J. Roboz, Eric J. Feldman, Duane C. Hassane, Oliver G. Ottmann, Jörge E. Cortes, Mónica L. Guzmán, Jeffrey E. Lancet, Pinkal Desai, Jonathan E. Kolitz and Nuria Mencia-Trinchant and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Ellen K. Ritchie
165 papers receiving 3.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ellen K. Ritchie United States | 30 | 2.4k | 1.4k | 1.2k | 736 | 678 | 172 | 3.6k | ||
| Tibor Kovacsovics United States | 29 | 2.3k 0.9× | 1.4k 1.0× | 639 0.5× | 1.1k 1.5× | 880 1.3× | 123 | 3.7k | ||
| Ellin Berman United States | 31 | 2.2k 0.9× | 1.2k 0.9× | 992 0.8× | 871 1.2× | 1.2k 1.8× | 99 | 3.8k | ||
| Norbert Gattermann Germany | 26 | 3.6k 1.5× | 1.7k 1.3× | 1.6k 1.3× | 672 0.9× | 439 0.6× | 55 | 4.5k | ||
| Yesid Alvarado United States | 26 | 1.6k 0.7× | 777 0.6× | 816 0.7× | 533 0.7× | 573 0.8× | 153 | 2.4k | ||
| Claude Gardin France | 35 | 3.2k 1.3× | 1.9k 1.4× | 1.1k 0.9× | 800 1.1× | 750 1.1× | 123 | 4.3k | ||
| Stefan Faderl United States | 26 | 2.0k 0.8× | 1.2k 0.9× | 1.7k 1.4× | 519 0.7× | 548 0.8× | 115 | 3.6k | ||
| Amir T. Fathi United States | 34 | 2.3k 1.0× | 1.7k 1.3× | 703 0.6× | 769 1.0× | 984 1.5× | 203 | 3.8k | ||
| H. Kantarjian United States | 29 | 2.4k 1.0× | 995 0.7× | 2.1k 1.8× | 781 1.1× | 637 0.9× | 120 | 3.9k | ||
| Hélène A. Poirel Belgium | 23 | 778 0.3× | 804 0.6× | 637 0.5× | 342 0.5× | 674 1.0× | 56 | 2.1k | ||
| Prithviraj Bose United States | 32 | 2.2k 0.9× | 1.9k 1.4× | 1.9k 1.6× | 281 0.4× | 709 1.0× | 277 | 4.0k |
Countries citing papers authored by Ellen K. Ritchie
Since
Specialization
Citations
This map shows the geographic impact of Ellen K. Ritchie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen K. Ritchie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen K. Ritchie more than expected).
Fields of papers citing papers by Ellen K. Ritchie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ellen K. Ritchie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen K. Ritchie. The network helps show where Ellen K. Ritchie may publish in the future.
Co-authorship network of co-authors of Ellen K. Ritchie
This figure shows the co-authorship network connecting the top 25 collaborators of Ellen K. Ritchie. A scholar is included among the top collaborators of Ellen K. Ritchie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen K. Ritchie. Ellen K. Ritchie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kremyanskaya, Marina, Andrew Kuykendall, Naveen Pemmaraju, et al.. (2024). Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. New England Journal of Medicine. 390(8). 723–735.
2.
Scandura, Joseph M., et al.. (2023). A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044). Blood. 142(Supplement 1). 3211–3211.
3.
Pemmaraju, Naveen, Marina Kremyanskaya, Andrew Kuykendall, et al.. (2023). MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study. Clinical Lymphoma Myeloma & Leukemia. 23. S400–S401.
4.
Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059.
5.
Abu‐Zeinah, Ghaith, Silvana Di Giandomenico, Daniel Choi, et al.. (2022). Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Advances. 6(18). 5477–5481.
6.
Kasner, Margaret, Molly B. Halloran, Ellen K. Ritchie, et al.. (2022). A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Investigational New Drugs. 40(4). 773–781.
7.
Abu‐Zeinah, Ghaith, et al.. (2021). Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 35(9). 2592–2601.
8.
Patel, Sanjay S., Julia T. Geyer, Joelle Racchumi, et al.. (2021). Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in Oncology. 11. 701318–701318.
9.
Lindsley, R. Coleman, Christopher J. Gibson, H. Moses Murdock, et al.. (2019). Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 15–15.
10.
Ryan, Daniel, Laura F. Newell, Ellen K. Ritchie, et al.. (2019). Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Blood. 134(Supplement_1). 3842–3842.
11.
Gergis, Usama, Tsiporah B. Shore, Sebastian Mayer, et al.. (2018). Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of Blood and Marrow Transplantation. 25(3). 466–473.
12.
Martinelli, Giovanni, Nicolas Boissel, Patrice Chevallier, et al.. (2017). Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology. 35(16). 1795–1802.
13.
Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334.
14.
Mencia-Trinchant, Nuria, Yang Hu, Bas J. Wouters, et al.. (2017). Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. Journal of Molecular Diagnostics. 19(4). 537–548.
15.
Ritchie, Ellen K., Dominick Latrémouille-Viau, Annie Guérin, et al.. (2017). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation. Blood. 130. 3396–3396.
16.
Ritchie, Ellen K., Gail J. Roboz, Richard T. Silver, et al.. (2017). Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood. 130. 2910–2910.
17.
Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, et al.. (2017). Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. Blood. 130. 2875–2875.
18.
Kane, Kathleen, Pinkal Desai, Michael Samuel, et al.. (2017). Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy. Blood. 130. 3870–3870.
19.
Chen, Katherine, et al.. (2017). Acute myeloid leukemia in a patient with thrombocytopenia with absent radii. Hematology/Oncology and Stem Cell Therapy. 11(4). 245–247.
20.
Park, Jae H., Ellen K. Ritchie, Arati V. Rao, et al.. (2016). A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial. Blood. 128(22). 1629–1629.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tibor Kovacsovics Breakdown of academic impact, for papers by Ellin Berman Breakdown of academic impact, for papers by Norbert Gattermann Breakdown of academic impact, for papers by Yesid Alvarado Breakdown of academic impact, for papers by Claude Gardin Breakdown of academic impact, for papers by Stefan Faderl Breakdown of academic impact, for papers by Amir T. Fathi Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Hélène A. Poirel Breakdown of academic impact, for papers by Prithviraj Bose